Cytomedix Inc. New (CMXI) 0.4600 $CMXI
Xstelos Holdings Inc. Sees Surge in Volume Despite Lack of News
ACCESSWIRE - Wed May 07, 9:30AM CDT
Xstelos Holdings Inc.'s (OTCPINK: XTLS) share volume skyrocketed on May 6th, with 2,869,020 shares exchanging hands, over 64 times greater than its three month daily average of 44,170 shares.
Cytomedix Announces Results of RECOVER-Stroke Phase 2 Study; Provides Update on R&D Reorganization and Ongoing Launch Initiatives for AutoloGel(TM)
GlobeNewswire - Mon May 05, 3:41PM CDT
Results from RECOVER-Stroke Phase 2 Trial Show No Significant Clinical Benefit; Completion of R&D Restructuring Expected to Lead to Additional Cost Savings;
Cytomedix Announces Two AutoloGel(R) Presentations at the Symposium on Advanced Wound Care (SAWC) Spring Meeting
GlobeNewswire - Tue Apr 22, 3:19PM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced two key oral presentations and a poster presentation highlighting AutoloGel will be made at the Symposium on Advanced Wound Care (SAWC) Spring Meeting, being held April 23-27, 2014, at the Gaylord Palms Hotel & Convention Center, in Orlando Florida. Cytomedix will also have an exhibition booth at the meeting (#901).
Cytomedix appoints Andrew Cohen as VP of Marketing
M2 - Tue Apr 08, 6:14AM CDT
Regenerative therapies company Cytomedix (Other OTC:CMXI) revealed on Monday the addition of Andrew Cohen as vice president of its Marketing.
Cytomedix Announces Appointment of Andrew Cohen as Vice President of Marketing
GlobeNewswire - Mon Apr 07, 7:00AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today the appointment of Andrew Cohen as Vice President of Marketing. He will have overall marketing responsibilities as the Company moves forward with its commercial plan to launch AutoloGel in the wound care market. He will report to Dean Tozer, Executive Vice President and Chief Commercial Officer.
Deerfield Announces a $35 Million Dollar Investment Commitment to Cytomedix, Inc.
Business Wire - Mon Mar 31, 3:45PM CDT
Deerfield Management Company announced today that it has committed to invest up to $35 million dollars in Cytomedix, Inc. (OTCQX: CMXI) through a senior secured convertible debt facility with warrants.
Cytomedix Announces Senior Management Appointments
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results; Announces Up to $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Mon Mar 31, 3:37PM CDT
$2 Million Additional Equity Investment with Anson Group
Cytomedix to Host Fourth Quarter & Fiscal Year End 2013 Financial Results Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and twelve-month period ended December 31, 2013, after the close of the market on Monday, March 31, 2014.
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.
Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".
Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.
Cytomedix Announces Final Payment Decision From the Centers for Medicare & Medicaid Services for the AutoloGel(TM) System
Marketwire - Mon Dec 02, 7:01AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today that the Centers for Medicare & Medicaid Services (CMS) has issued final Medicare payment regulations for the Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS), which allow for ample payment for use of the AutoloGel(TM) System for the treatment of chronic, non-healing wounds. These rules will take effect January 1, 2014.
Market Research: Lysosomal Storage Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 20, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j39q2v/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2013" report to their offering. 'Lysosomal Storage Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Scope - A snapshot of the global therapeutic scenario for Lysosomal Storage Disorder. - A review of the Lysosomal Storage Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lysosomal Storage Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sangamo BioSciences, Inc. BioMarin Pharmaceutical Inc. Neuralstem, Inc. Amicus Therapeutics, Inc. Cytomedix, Inc. AngioChem Inc. Zymenex A/S Synageva BioPharma Corp. Fate Therapeutics, Inc. REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/j3...al_storage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cytomedix Reports Third Quarter 2013 Financial Results and Begins Supplying AutoloGel to Treat Medicare Patients
Marketwire - Tue Nov 12, 3:45PM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the third quarter of 2013 and announced the initiation of AutoloGel sales to treat Medicare beneficiaries under the Coverage with Evidence Development (CED) program and the Physician Fee Schedule (PFS).
Cytomedix Provides Update on Reimbursement Progress for AutoloGel(TM) in the Hospital Outpatient Prospective Payment System (HOPPS)
Marketwire - Wed Sep 18, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today provided an update on recent progress in attaining appropriate reimbursement for AutoloGel(TM) in the Medicare Hospital Outpatient Prospective Payment System (HOPPS). The Company has filed public comments with the Centers for Medicare and Medicaid Services (CMS) on the previously announced proposed rules for HOPPS and recently held a direct meeting with CMS. Based on these interactions, Cytomedix believes that CMS now has all the information required to make a final and fully informed decision on AutoloGel reimbursement in the hospital outpatient setting.
Cytomedix Announces Strategic Reorganization of Research and Development Operations
Marketwire - Tue Sep 17, 3:01PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative cell based technologies, today announced that, in line with its strategy to build a profitable and successful company commercially focused on the wound care market, it will reorganize its research and development activities. As part of this initiative, the Company's ongoing financial support of the current RECOVER-Stroke trial and the underlying ALDH Bright Cell technology will be substantially concluded as of year-end 2013. The Company is exploring a range of strategic options for continuing its clinical programs beyond year-end 2013, which options may include, among others, technology transfer, spinout, licensing or other similar transactions involving the underlying technology.
OTC Daily Alert Stock Watch - Cytomedix, Inc (OTCQX: CMXI)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Xstelos Holdings Inc. Sees Surge in Volume Despite Lack of News
ACCESSWIRE - Wed May 07, 9:30AM CDT
Xstelos Holdings Inc.'s (OTCPINK: XTLS) share volume skyrocketed on May 6th, with 2,869,020 shares exchanging hands, over 64 times greater than its three month daily average of 44,170 shares.
Cytomedix Announces Results of RECOVER-Stroke Phase 2 Study; Provides Update on R&D Reorganization and Ongoing Launch Initiatives for AutoloGel(TM)
GlobeNewswire - Mon May 05, 3:41PM CDT
Results from RECOVER-Stroke Phase 2 Trial Show No Significant Clinical Benefit; Completion of R&D Restructuring Expected to Lead to Additional Cost Savings;
Cytomedix Announces Two AutoloGel(R) Presentations at the Symposium on Advanced Wound Care (SAWC) Spring Meeting
GlobeNewswire - Tue Apr 22, 3:19PM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced two key oral presentations and a poster presentation highlighting AutoloGel will be made at the Symposium on Advanced Wound Care (SAWC) Spring Meeting, being held April 23-27, 2014, at the Gaylord Palms Hotel & Convention Center, in Orlando Florida. Cytomedix will also have an exhibition booth at the meeting (#901).
Cytomedix appoints Andrew Cohen as VP of Marketing
M2 - Tue Apr 08, 6:14AM CDT
Regenerative therapies company Cytomedix (Other OTC:CMXI) revealed on Monday the addition of Andrew Cohen as vice president of its Marketing.
Cytomedix Announces Appointment of Andrew Cohen as Vice President of Marketing
GlobeNewswire - Mon Apr 07, 7:00AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today the appointment of Andrew Cohen as Vice President of Marketing. He will have overall marketing responsibilities as the Company moves forward with its commercial plan to launch AutoloGel in the wound care market. He will report to Dean Tozer, Executive Vice President and Chief Commercial Officer.
Deerfield Announces a $35 Million Dollar Investment Commitment to Cytomedix, Inc.
Business Wire - Mon Mar 31, 3:45PM CDT
Deerfield Management Company announced today that it has committed to invest up to $35 million dollars in Cytomedix, Inc. (OTCQX: CMXI) through a senior secured convertible debt facility with warrants.
Cytomedix Announces Senior Management Appointments
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results; Announces Up to $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Mon Mar 31, 3:37PM CDT
$2 Million Additional Equity Investment with Anson Group
Cytomedix to Host Fourth Quarter & Fiscal Year End 2013 Financial Results Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and twelve-month period ended December 31, 2013, after the close of the market on Monday, March 31, 2014.
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.
Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".
Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.
Cytomedix Announces Final Payment Decision From the Centers for Medicare & Medicaid Services for the AutoloGel(TM) System
Marketwire - Mon Dec 02, 7:01AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today that the Centers for Medicare & Medicaid Services (CMS) has issued final Medicare payment regulations for the Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS), which allow for ample payment for use of the AutoloGel(TM) System for the treatment of chronic, non-healing wounds. These rules will take effect January 1, 2014.
Market Research: Lysosomal Storage Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 20, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j39q2v/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2013" report to their offering. 'Lysosomal Storage Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Scope - A snapshot of the global therapeutic scenario for Lysosomal Storage Disorder. - A review of the Lysosomal Storage Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lysosomal Storage Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sangamo BioSciences, Inc. BioMarin Pharmaceutical Inc. Neuralstem, Inc. Amicus Therapeutics, Inc. Cytomedix, Inc. AngioChem Inc. Zymenex A/S Synageva BioPharma Corp. Fate Therapeutics, Inc. REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/j3...al_storage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cytomedix Reports Third Quarter 2013 Financial Results and Begins Supplying AutoloGel to Treat Medicare Patients
Marketwire - Tue Nov 12, 3:45PM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the third quarter of 2013 and announced the initiation of AutoloGel sales to treat Medicare beneficiaries under the Coverage with Evidence Development (CED) program and the Physician Fee Schedule (PFS).
Cytomedix Provides Update on Reimbursement Progress for AutoloGel(TM) in the Hospital Outpatient Prospective Payment System (HOPPS)
Marketwire - Wed Sep 18, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today provided an update on recent progress in attaining appropriate reimbursement for AutoloGel(TM) in the Medicare Hospital Outpatient Prospective Payment System (HOPPS). The Company has filed public comments with the Centers for Medicare and Medicaid Services (CMS) on the previously announced proposed rules for HOPPS and recently held a direct meeting with CMS. Based on these interactions, Cytomedix believes that CMS now has all the information required to make a final and fully informed decision on AutoloGel reimbursement in the hospital outpatient setting.
Cytomedix Announces Strategic Reorganization of Research and Development Operations
Marketwire - Tue Sep 17, 3:01PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative cell based technologies, today announced that, in line with its strategy to build a profitable and successful company commercially focused on the wound care market, it will reorganize its research and development activities. As part of this initiative, the Company's ongoing financial support of the current RECOVER-Stroke trial and the underlying ALDH Bright Cell technology will be substantially concluded as of year-end 2013. The Company is exploring a range of strategic options for continuing its clinical programs beyond year-end 2013, which options may include, among others, technology transfer, spinout, licensing or other similar transactions involving the underlying technology.
OTC Daily Alert Stock Watch - Cytomedix, Inc (OTCQX: CMXI)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
